Waters

Thursday, June 23, 2022 at 10am ET | 3pm BST | 4pm CEST Join us on June 23 to learn about QC Analysis of Oligonucleotide Therapeutics. One Platform Method for Determining Identity, Purity, and Quantity.

Medical Devices: Minimizing the Risk of Non-Compliance Through Enhanced Chemical Testing

ByWaters

May 4th 2021

PharmTech Sponsored eBooks

Challenges with Extractables and Leachables in Medical Devices

ByWaters

March 23rd 2021

Extractables and Leachables in Medical Devices: Challenges and Considerations

ByWaters

March 22nd 2021

Sponsored Content

Waters

Articles by Waters

Adding Mass Detection to UV Workflows: Reducing Analytical Risk with the ACQUITY QDa II Mass Detector and Empower Software

ACQUITY QDa II Mass Detector Advancing the Power of Mass Detection

Analytical Quality by Design Based Method Development for the Analysis of Cold and Cough Formulations Using an Arc™ Premier System

Streamlining Impurity Analysis in Atorvastatin with the ACQUITY™ QDa™ II Mass Detector for Enhanced Detection and Quantification

Updates in Small Molecule Pharmaceutical Development

Quality Control Analysis of Oligonucleotide Therapeutics: One Platform Method for Determining Identity, Purity, and Quantity

QC Analysis of Oligonucleotide Therapeutics: One Platform Method for Determining Identity, Purity, and Quantity

Medical Devices: Minimizing the Risk of Non-Compliance Through Enhanced Chemical Testing

Challenges with Extractables and Leachables in Medical Devices

Extractables and Leachables in Medical Devices: Challenges and Considerations

Latest Updated Articles

Trending on Pharmaceutical Technology

Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data

Everything to Know about BMS & NVidia’s AI Supercomputer

Can AI Fix Pharma's Last-Mile Delivery Blind Spot?

Midyear 2026 Check-In: Megha Sinha on Pharma's AI Skills Gap

From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026